CDKN2A and lung adenocarcinoma: Survival analysis revealed that in patients with stage I lung adenocarcinoma, those who lacked CDKN2A expression had worse overall survival compared with those with normal CDKN2A expression (median 86.63 months vs. not reached, P = 0.008; Figure 5A).